Home
The Facility
Services
Our Team
Jobs
Contact Us
More
Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, et al. A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. Clin Transl Immunology. 2022;11(3):e1380.
Collins E, Galipeau Y, Arnold C, Bosveld C, Heiskanen A, Keeshan A, et al. Cohort profile: Stop the Spread Ottawa (SSO)-a community-based prospective cohort study on antibody responses, antibody neutralisation efficiency and cellular immunity to SARS-CoV-2 infection and vaccination. BMJ Open. 2022;12(9):e062187.
Cholette F, Fabia R, Harris A, Ellis H, Cachero K, Schroeder L, et al. Comparative performance data for multiplex SARS-CoV-2 serological assays from a large panel of dried blood spot specimens. Heliyon. 2022;8(9):e10270.
Statistics Canada. 2022, September 06. Self-reported COVID-19 test results in Canada, January 2020 to March 2022. [Press Release]
Unninayar D, Falcone EL, Chapdelaine H, Vinh DC, Top KA, Derfalvi B, et al. Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections. Frontiers in Immunology. 2025;15.
Tsampalieros A, Zemek R, Barrowman N, Langlois MA, Arnold C, McGahern C, et al. Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years. Vaccine. 2024.
Santerre K, Theriault M, Brousseau N, Langlois MA, Arnold C, Pelletier JN, et al. Infection Rate and Risk Factors of SARS-CoV-2 Infection in Retail Workers at the Onset of the COVID-19 Pandemic, Quebec, Canada. Infect Dis Rep. 2024;16(6):1240-53.
Almeida ND, Schiller I, Ke D, Sakr E, Plesa M, Vanamala S, et al. The effect of dose-interval on antibody response to mRNA COVID-19 vaccines: a prospective cohort study. Frontiers in Immunology. 2024;15.
Cuperlovic-Culf M, Bennett SAL, Galipeau Y, McCluskie PS, Arnold C, Bagheri S, et al. Multivariate analyses and machine learning link sex and age with antibody responses to SARS-CoV-2 and vaccination. iScience. 2024;27(8):110484.
Collins E, Galipeau Y, Arnold C, Bhereur A, Booth R, Buchan AC, et al. Clinical and serological predictors of post COVID-19 condition-findings from a Canadian prospective cohort study. Front Public Health. 2024;12:1276391.
Statistics Canada. 2024, Aug 21. COVID-19: Longer-term symptoms among Canadian adults - Fourth Report.
Costiniuk CT, Lee T, Singer J, Galipeau Y, Arnold C, Langlois MA, et al. Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study. Vaccines (Basel). 2024;12(5).
D'Souza M, Keeshan A, Gravel CA, Langlois MA, Cooper CL. Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity. NPJ Vaccines. 2024;9(1):226.
Bhella S, Wilkin AM, Hueniken K, Vijenthira A, Sebag M, Wang P, et al. COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies. Vaccine. 2024;42(24):126074.
Bhella SD, Wilkin AM, Hueniken K, Vijenthira A, Sebag M, Wang P, et al. COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy. Blood. 2024;144(Supplement 1):286-.
Sakr E, Almeida ND, Langlois MA, Dasgupta K, Mazer BD. Booster doses of COVID-19 vaccine enhance neutralization efficiency against XBB.1.5. J Allergy Clin Immunol. 2023.
Fakhraei R, Erwin E, Alibhai KM, Murphy MSQ, Dingwall-Harvey ALJ, White RR, et al. Prevalence of SARS-CoV-2 infection among obstetric patients in Ottawa, Canada: a descriptive study. CMAJ Open. 2022;10(3):E643-E51.
Whelan M, Galipeau Y, White-Al Habeeb N, Konforte D, Abou El Hassan M, Booth RA, et al. Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals. Open Forum Infect Dis. 2023;10(8):ofad384.
Keeshan A, Galipeau Y, Heiskanen A, Collins E, McCluskie PS, Arnold C, et al. Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination. BMJ Open. 2023;13(10):e077714.
Azeez R, Lotoski L, Dubeau A, Rodriguez N, Reyna ME, Freitas T, et al. Cohort profile: investigating SARS-CoV-2 infection and the health and psychosocial impact of the COVID-19 pandemic in the Canadian CHILD Cohort. Epidemiol Health. 2023;45:e2023091.
